Company Update (NYSE:JNJ): Johnson & Johnson gets $1.2 billion Arkansas Risperdal judgment tossed out

Johnson & Johnson (NYSE:JNJ) [Reuters] – Johnson & Johnson on Thursday won a reversal by the Arkansas Supreme Court of a $1.2 billion judgment imposed after a jury concluded that the drugmaker improperly marketed its anti-psychotic drug Risperdal …
Read more on this.

Johnson & Johnson (JNJ), with a current value of $265.76B, started trading this morning at $93.52.
 
Looking at the stock, its one day range is $92.97 to $94.09 and has traded between $78.77 and $95.99 over the past year.
 
JNJ shares are currently priced at 16.05x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s 8.01x earnings multiple.
 
The company pays shareholders $2.64 per share annually in dividends, yielding 2.80%.
 
According to a consensus of 16 analysts, the earnings estimate of $1.48 per share would be $0.04 better than the year-ago quarter and a $0.00 sequential decrease. The full-year EPS estimate is $5.83 which would be a $0.31 better than last year’s full-year earnings.
 
The quarterly earnings estimate is predicated on a consensus revenue forecast of $18.00 Billion. If reported, that would be a 2.86% increase over the year-ago quarter.
 
More recently, Barclays downgraded JNJ from Overweight to Equal Weight (Jan 10, 2014). Previously, RBC Capital Mkts upgraded JNJ from Sector Perform to Outperform.
 
The average price target for JNJ shares by the analysts covering it is $101.08, which is 8.08% above where the stock opened.
 
Summary (NYSE:JNJ) :  Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The Consumer segment offers a range of products used in the baby care, skin care, oral care, wound care, and women’s health fields, as well as nutritionals, over-the-counter pharmaceutical products, and wellness and prevention platforms under the JOHNSON’S, AVEENO, CLEAN & CLEAR, DABAO, JOHNSON’S Adult, LUBRIDERM, NEUTROGENA, RoC, VENDÔME, LISTERINE, BAND-AID, NEOSPORIN, STAYFREE, CAREFREE, o.b. tampon, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID brand names. This segment markets its products to the general public, as well as to retail outlets and distributors. The Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, cardiovascular, contraceptive, gastrointestinal, hematology, immunology, infectious diseases, metabolic, neurology, oncology, pain management, thrombosis, and vaccines. This segment distributes its products directly to retailers, wholesalers, and health care professionals for prescription use. The Medical Devices and Diagnostics segment offers various products to treat cardiovascular disease; orthopaedic and neurological products; blood glucose monitoring and insulin delivery products; general surgery, biosurgical, and energy products; professional diagnostic products; infection prevention products; and disposable contact lenses. This segment distributes its products to wholesalers, hospitals, and retailers, used principally in the professional fields by physicians, nurses, hospitals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
 
Tag Helper ~ Stock Code: JNJ | Common Company name: Johnson & Johnson | Full Company name: Johnson & Johnson (NYSE:JNJ) .

More on this topic (What's this?) Read more on JOHNSON & JOHNSON at Wikinvest

Sharing the News


facebooktwittergoogle_plusredditlinkedinmail

Follow us for the Latest news


facebooktwittergoogle_pluslinkedinrss

NYSE, NASDAQ, Market Data, Earnings Estimates, Analyst Ratings and Key Statistics provided via Yahoo Finance, unless otherwise specified. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Jutia Group will not be liable for any errors, incompleteness or delays, or for any actions taken in reliance on the data displayed herein.

Related Articles


Comments are closed.